Lefamulin - a recently developed antibiotic for treatment of community-acquired bacterial pneumonia (CABP)
DOI:
https://doi.org/10.12775/JEHS.2023.15.01.018Keywords
lefamulin, BC3781, pleuromutilin, CABP, pneumonia, community acquired pneumoniaAbstract
Introduction and aim. Nowadays, the increasing resistance of bacteria is a concerning and challenging issue in terms of effective treatment of bacterial infections. The amount of available antibiotics has been quite constant for many years. The search for substances alternative to older classes of drugs, among which resistance is growing, has been ongoing for years. One of the newly introduced available alternatives is lefamulin. The aim of this paper is to present the potential benefits of its use in comunity-acquired bacterial pneumonia (CABP).
Material and methods. A review of the available literature was performed by searching the PubMed and GoogleScholar databases using the following key words: lefamulin; BC3781; pleuromutilin; CABP; community acquired pneumonia.
Analysis of literature. Lefamulin is a bacteriostatic antibiotic from the group of pleuromutilins, which has a unique mechanism of action consisting in binding to the bacterial 50S ribosomal subunit in the peptidyl transferase center. Thanks to this, it rarely causes resistance among other groups of antibiotics and is characterized by a safe action profile. Its spectrum of action includes bacteria causing CABP. In phase III studies, the efficacy of lefamulin monotherapy was comparable to that of moxifloxacin with or without linezolid in CABP. Thanks to broad spectrum of action its usefulness may also extend to treatment of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and multidrug-resistant organisms associated with sexually transmitted infections, e.g., Neisseria gonorrhoeae, Mycoplasma genitalium, although more additional clinical and pharmacodynamic data is needed.
Conclusion. Lefamulin is a promising addition to the antibiotic armamentarium for treating CABP. Its unique mechanism of action, activity against typical and atypical bacteria, flexible dosing options, and favorable safety profile make it a beneficial choice for clinicians.
References
Adhikary S, Duggal MK, Nagendran S et al. Lefamulin: a New Hope in the Field of Community-Acquired Bacterial Pneumonia. Curr Pharmacol, 2022;8:418–426. doi: 10.1007/s40495-022-00297-6
Label (PDF)-FDA. XENLETA (Lefamulin). Highlights of prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211672s000,211673s000lbl.pdf. Accessed March 1, 2023.
Watkins RR, File TM. Lefamulin: A Novel Semisynthetic Pleuromutilin Antibiotic for Community-acquired Bacterial Pneumonia. Clin Infect Dis. 2020;71(10):2757-2762. doi: 10.1093/cid/ciaa336
Veve MP, Wagner JL. Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic. Pharmacotherapy. 2018;38(9):935-946. doi: 10.1002/phar.2166
Novak R, Shlaes DM. The pleuromutilin antibiotics: a new class for human use. Curr Opin Investig Drugs. 2010;11(2):182–191.
Eyal Z, Matzov D, Krupkin M, et al. Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus. Proc Natl Acad Sci U S A. 2015;112(43):5805–5814.
Paukner S, Riedl R. Pleuromutilins: potent drugs for resistant bugs-mode of action and resistance. Cold Spring Harb Perspect Med 2017; 7 pii: a027110. doi:10.1101/cshperspect.a027110
Mendes RE, Paukner S, Doyle TB, Gelone SP, Flamm RK, Sader HS. Low Prevalence of Gram-Positive Isolates Showing Elevated Lefamulin MIC Results during the SENTRY Surveillance Program for 2015-2016 and Characterization of Resistance Mechanisms. Antimicrob Agents Chemother. 2019;63(4):02158–18.
Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). Antimicrob Agents Chemother. 2019 Mar 27;63(4):02161-18. doi: 10.1128/AAC.02161-18
Paukner S, Sader HS, Ivezic-Schoenfeld Z, et al. Antimicrobial activity of the pleuromutilin antibiotic BC-3781 against bacterial pathogens isolated in the SENTRY antimicrobial surveillance program in 2010. Antimicrob Agents Chemother 2013; 57: 4489–95.
Sader HS, Biedenbach DJ, Paukner S, et al. Antimicrobial activity of the investigational pleuromutilin compound BC-3781 tested against gram-positive organisms commonly associated with acute bacterial skin and skin structure infections. Antimicrob Agents Chemother 2012; 56: 1619–23.
Sader HS, Paukner S, Ivezic-Schoenfeld Z, Biedenbach DJ, Schmitz FJ, Jones RN. Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). J Antimicrob Chemother. 2012;67(5):1170-5. doi: 10.1093/jac/dks001
Paukner S, Gruss A, Jensen JS. In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens. Antimicrob Agents Chemother. 2018;62(5):e02380-17. doi: 10.1128/AAC.02380-17
Jacobsson S, Paukner S, Golparian D, Jensen JS, Unemo M. In Vitro Activity of the Novel Pleuromutilin Lefamulin (BC-3781) and Effect of Efflux Pump Inactivation on Multidrug-Resistant and Extensively Drug-Resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2017;61(11):e01497-17. doi: 10.1128/AAC.01497-17
Paukner S, Gelone SP, Arends SJR, Flamm RK, Sader HS. Antibacterial Activity of Lefamulin against Pathogens Most Commonly Causing Community-Acquired Bacterial Pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). Antimicrob Agents Chemother. 2019;63(4):e02161-18. doi: 10.1128/AAC.02161-18
Hryniewicz W, Albrecht P, Radzikowski A (red.). Rekomendacje postępowania w pozaszpitalnych zakażeniach układu oddechowego. Warszawa: Narodowy Instytut Leków, 2017
Główny Urząd Statystyczny. Rocznik Demograficzny 2020. Warszawa 2020
Torres A, Peetermans WE, Viegi G, Blasi F. Risk factors for community-acquired pneumonia in adults in Europe: A literature review. Thorax. 2013;68(11):1057-1065. doi:10.1136/thoraxjnl-2013-204282
Pneumococcal disease - transmission and those at high risk. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/pneumococcal/about/risk-transmission.html Accessed March 17, 2023.
Regunath H, Oba Y. Community-Acquired Pneumonia. https://www.ncbi.nlm.nih.gov/books/NBK430749/. Updated Feb 11, 2019. Accessed March 3, 2023.
Brown JS. Community-acquired pneumonia. Clin Med (Lond). 2012;12(6):538-543. doi:10.7861/clinmedicine.12-6-538
File Jr TM, Goldberg L, Das A, et al. Efficacy and safety of intravenous-to-oral lefamulin, a pleuromutilin antibiotic, for the treatment of community-acquired bacterial pneumonia: the phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) trial. Clin Infect Dis. 2019;69(11):1856–1867.
Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. 2019 Nov 5;322(17):1661-1671. doi: 10.1001/jama.2019.15468
Nabriva Therapeutics Receives U.S. FDA Approval of Xenleta™ (lefamulin) to Treat Community-Acquired Bacterial Pneumonia (CABP). http://https://investors.nabriva.com/news-releases/news-releasedetails/nabriva-therapeutics-receives-us-fda-approval-xenleta. Published: 2019. Accessed March 1, 2023.
Wicha WW, Ivezic-Schoenfeld Z, Novak R. Pre-clinical efficacy of BC-3781 in thigh and bacteremia infections caused by staphylococci. https://www.nabriva.com/Portals/_default/Skins/ProfessionalUs/pdfs/2010-%20efficacy-bc-3781-thigh-bacteremia-and-staph.pdf. Accessed June 18, 2023.
Fischer E, Kappes BC, Wicha WW. Efficacy of Lefamulin Against Staphylococcus aureus-Induced Bacteremia in a Neutropenic and Immunocompetent Murine Model. Open Forum Infect Dis. 2017;4(Suppl 1):S471. doi: 10.1093/ofid/ofx163.1205
Mercuro NJ, Davis SL, Zervos MJ, Herc ES. Combatting resistant enterococcal infections: a pharmacotherapy review. Expert Opin Pharmacother. 2018;19(9):979–992.
DiPippo A, Tverdek FP, Tarrand JJ, et al. Daptomycin non-susceptible Enterococcus faecium in leukemia patients: role of prior daptomycin exposure. J Inf Secur. 2017;74(3):243–247.
Antibiotic Resistance Threats in the United States. Centers for Disease Control and Prevention Web site. https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Published 2019. Accessed March 17, 2023.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Leila Abod, Natalia Ilnicka, Daria Matyja, Maria Sadlik, Patrycja Zuziak
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 390
Number of citations: 0
